Trial Profile
A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal-vaccine-group-B-OMV-GlaxoSmithKline/Finlay (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2013 New source identified and integrated (ClinicalTrials.gov; NCT00137917).
- 05 Nov 2010 New trial record.